1. P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION. (23rd June 2022) Authors: Passamonti, F.; Lou, Y.; Chevli, M.; Abraham, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 948 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS. (23rd June 2022) Authors: Abraham, P.; Liao, X.; Chevli, M.; Smith, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 951 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗